Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | New hopes for the treatment of Parkinson’s disease

Gennaro Pagano, MD, MSc, PhD, Roche Pharma Research & Early Development, Basel, Switzerland, discusses the exciting developments in detecting and measuring key pathological findings in Parkinson’s disease. Dr Pagano highlights the ability to measure the presence of pathogenic proteins in the cerebrospinal fluid (CSF) and the new staging system that can potentially identify individuals at risk before symptoms occur. This early identification opens up possibilities for developing therapeutics to prevent disease onset. However, more research is needed to understand the temporal dynamics and the specific targets and drivers in each individual’s disease progression. Overall, these advancements provide a valuable framework for positioning drug development and testing. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Pagano is a full-time employee and shareholder at F. Hoffmann – La Roche Ldt.